|Values are valid only on day of printing.|
Updated: December 2014
Published: January 2013
Problems playing the video? View it on Mayo Clinic's YouTube Channel.
The genetic aberrations present in multiple myeloma cells play a significant role in the risk stratification and therapeutic approach in multiple myeloma patients. Mayo Stratification for Myeloma and Risk-Adapted Therapy (mSMART ) represents a consensus opinion on the utilization and assessment of these genetic markers in multiple myeloma. A report summarizing the genetic profile of the plasma cells and the subsequent risk classification according to the mSMART algorithm is routinely provided.
For additional treatment guidelines visit mSMART.org
Mayo Clinic determines plasma cell proliferation rate using a flow cytometric assay that measures the S-phase of neoplastic plasma cells by detection of DAPI nuclear staining. The new assay provides important prognostic information in multiple myeloma, including the percent clonal plasma cells, percent polyclonal plasma cells, proliferation rate of the clonal plasma cells, and DNA content.
Flow cytometric immunophenotyping offers several advantages: